-
Prevalence of thyroid cancer in patients with acromegaly and non-growth hormone secreting pituitary adenomas: A prospective cross-sectional study Growth Horm. IGF Res. (IF 1.618) Pub Date : 2021-01-12 Isadora Yasbick Spricido; Carolina Monteguti Feckinghaus; Rômulo Henrique Malaquias Silva; Cleo Otaviano Mesa Junior; Cesar Luiz Boguszewski
Objective: To evaluate the prevalence of differentiated thyroid cancer (DTC) in patients with non-GH secreting pituitary adenomas [NGHPA group: non-functioning (NFPA), prolactin (PRL) and corticotropin (ACTH)-secreting adenomas] compared to patients with acromegaly, a pituitary disease that has been associated with increased risk for thyroid cancer. Patients and Methods: Prospective, cross-sectional
-
Adult growth hormone deficiency: Optimizing transition of care from pediatric to adult services Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-12-10 Kevin C.J. Yuen; Craig A. Alter; Bradley S. Miller; Anthony W. Gannon; Nicholas A. Tritos; Susan L. Samson; Georgiana Dobri; Kristine Kurtz; Frank Strobl; Nicky Kelepouris
Objective Most patients with childhood-onset growth hormone deficiency (CO-GHD) receive treatment with exogenous growth hormone (GH) to facilitate the attainment of their full potential adult height. Recent evidence suggests that continuing GH administration during the transition period between the end of linear growth and full adult maturity is necessary for proper body composition and bone and muscle
-
Switching from originator recombinant growth hormone (Genotropin™) to biosimilar (CRISCY™): Results from a 6-month, multicentric, non-inferiority, extension trial. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-11-28 M.A. Czepielewski; Q. Garret; S.A.C. Vencio; N. Rassi; M.S. Faria; C.C.P. Senn; M.D. Bronstein; M.J.A.G. Cerqueira; A.C.L. Neves; A.M. Spinola-Castro; M.P.R. Cunha; N.R. Leite; G.E. Wassermann; M.C. Alegria; O. Toffoletto; J. Afiune; R. Baradelli; D.G. Rodrigues; M. Scharf
Objective: A previous 12-month comparative trial with Criscy™ (r-hGH Cristália), a biosimilar recombinant growth hormone, demonstrated equivalent efficacy and safety to Genotropin™. This extension trial evaluated the effects of switching patients treated with Genotropin™ to the biosimilar Criscy™ over an additional 6-month treatment period, comparing efficacy, safety, and immunogenicity parameters
-
Endothelial dysfunction in patients with acromegaly and It's association with Endocan Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-11-02 Seref Kul; Ozge Telci Caklili; Yasemin Tutuncu; Fatma Betul Ozcan; Feyza Aksu; Omer Faruk Baycan; Adem Atici; Ummuhan Zeynep Bilgili; Mumtaz Takir; Mustafa Caliskan
Objective This study aims to assess endocan levels in patients with acromegaly who have active disease or disease in remission and to investigate a relation between endocan levels and endothelial dysfunction in these patients. Design The study is a case-control study. Study was conducted at Istanbul Medeniyet University Goztepe Training and Research Hospital between 2013 and 2019. Patients who were
-
Effect of growth hormone treatment on circulating levels of NT-proBNP in patients with ischemic heart failure Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-10-11 Kristjan Karason; Emanuele Bobbio; Christian Polte; Entela Bollano; Magnus Peterson; Antonio Cittadini; Kenneth Caidahl; Åke Hjalmarson; Bengt-Åke Bengtsson; Jan Ekelund; Karl Swedberg; Jörgen Isgaard
Aims Growth hormone (GH) therapy in heart failure (HF) is controversial. We investigated the cardiovascular effects of GH in patients with chronic HF due to ischemic heart disease. Methods In a double-blind, placebo-controlled trial, we randomly assigned 37 patients (mean age 66 years; 95% male) with ischemic HF (ejection fraction [EF] < 40%) to a 9-month treatment with either recombinant human GH
-
A common deletion in the growth hormone receptor gene (d3-GHR) in the offspring is related to maternal placental GH levels during pregnancy Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-10-16 Rikke Beck Jensen; Malene Boas; John E. Nielsen; Lisa Leth Maroun; Anne Jørgensen; Torben Larsen; Katharina M. Main; Anders Juul
Background A common growth hormone receptor polymorphism with deletion of exon 3 (d3-GHR) has previously been linked to increased postnatal growth on the one hand and decreased fetal growth on the other. Regulation of fetal growth is positively dependent on secretion of placental GH (hGH-V). Objective We explored the effect of the fetal d3-GHR genotype on maternal serum levels of hGH-V and fetal growth
-
The inter – Test variability of growth hormone stimulation tests and factors affecting this variability Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-10-17 Eyal Ben Dori; Carmit Avnon Ziv; Adi Auerbach; Yael Greenberg; Hagit Zaken; Floris Levy-Khademi
Objective To evaluate the variability of growth hormone stimulation tests results and factors affecting it in short children suspected of having growth hormone deficiency. Design The cohort included patients with short stature suspected of having growth hormone deficiency, and who underwent a second stimulation test, after the first stimulation test was positive. Testing was done at a single center
-
Childhood growth hormone deficiency, a diagnosis in evolution: The intersection of growth hormone history and ethics Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-10-06 Rohan K. Henry
In 1958 the first recorded case of a patient treated with human growth hormone for growth hormone deficiency was published. Since that time, the source and availability of human growth hormone have changed. With the increased availability of growth hormone, there has been an uptrend in the level below which childhood growth hormone deficiency is diagnosed based on provocative GH stimulation testing
-
Molecular and cellular effects of insulin-like growth factor-1 and LongR3-IGF-1 on in vitro maturation of bovine oocytes: comparative study Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-09-25 M.S. Araujo; M.D. Guastali; F. Paulini; A.N. Silva; M.H. Tsunemi; P.K. Fontes; A.C.S. Castilho; F.C. Landim-Alvarenga
Addition effects of insulin-like growth factor-1 (IGF-1) and its synthetic analogue insulin-like growth factor-1 recombinant-3 (LongR3-IGF-1) after in vitro maturation (IVM) of cattle cumulus-oocyte complexes (COCs) were compared and evaluated on meiotic progression, apoptosis and profile genes of oocyte competence (GDF9, BMP15, BAX, BCL2, OOSP1, IGFBP2, IGBFP4 and IGFBP5), and their respective cumulus
-
Recovery using “float” from high intensity stress on growth hormone-like molecules in resistance trained men Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-09-25 William J. Kraemer; Lydia K. Caldwell; Emily M. Post; Matthew K. Beeler; Ryan M. Dickerson; Mary J. Kennett; Jeff S. Volek; Carl M. Maresh; Wesley C. Hymer
Objective The purpose of this study was to examine the influence of a novel “floatation-restricted environmental stimulation therapy” (floatation-REST) on growth hormone responses to an intense resistance exercise stress. Design Nine resistance trained men (age: 23.4 ± 2.5 yrs.; height: 175.3 ± 5.4 cm; body mass: 85.3 ± 7.9 kg) completed a balanced, crossover-controlled study design with two identical
-
Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-09-24 Hande Mefkure Ozkaya; Serdar Sahin; Ozge Polat Korkmaz; Emre Durcan; Humeyra Rekali Sahin; Emir Celik; Burc Cagri Poyraz; Pinar Kadioglu
Objective To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC). Design Forty patients with acromegaly, 40 with prolactinoma, 38 with NFA, and 32 HCs were included. All patients and controls were
-
Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: A hospital-based study of 237 cases Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-09-24 Ming Shen; Yeping Yang; Wenqiang He; Nidan Qiao; Min He; Xuefei Shou; Meng Wang; Zengyi Ma; Zhao Ye; Yichao Zhang; Zhengyuan Chen; Qilin Zhang; Xiang Zhou; Xiaoyun Cao; Hongying Ye; Yongfei Wang; Shiqi Li; Yiming Li; Zhaoyun Zhang
Objective To investigate the effectiveness and predictors of short-term somatostatin analog (SSA) presurgical therapy in a large cohort and to assess the correlation between clinical and pathological variables. Design 237 newly diagnosed patients with acromegaly received presurgical SSA treatment for three months were recruited. Clinical characteristics were collected, and response to SSA in hormone
-
Physical activity, dietary protein and insulin-like growth factor 1: Cross-sectional analysis utilising UK Biobank Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-09-24 C.N. Gulick; M.C. Peddie; C. Cameron; K. Bradbury; N.J. Rehrer
Background Insulin-like growth factor-I (IGF-1) is an anabolic hormone that stimulates cell growth and division. The effects of IGF-1 may be beneficial (muscle growth/repair) or detrimental (increased risk of several types of cancer and mortality) for health. Dietary protein and physical activity are thought to be factors that modulate IGF-1. Objective This study analysed the relationships dietary
-
Endoplasmic reticulum stress induces growth retardation by inhibiting growth hormone IGF-I axis. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-08-28 Wanjun Xia,Yajun Wang,Yong Zhang,Xin Ge,Pengwei Lv,Jingliang Cheng,Juncheng Wei
Objective Insulin-like growth factor 1 (IGFI) is one of several growth factors which is induced by growth hormone (GH), which activates the Janus kinase 2 (JAK2)-signal transducer and activator of transcription 5 (STAT5) pathway, and plays crucial roles in normal human growth, metabolism, and systemic energy homeostasis. However, little is known about the negative regulation of IGF-I production under
-
A single-center observational study assessing the predictive factors associated with the prognosis of acromegaly. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-08-27 Halit Diri,Ersin Ozaslan,Ali Kurtsoy,Fahri Bayram
Aim The aim of this study was to clarify the prognostic values of various preoperative factors, including the surgeon's ability as well as the patient's age, gender, tumor size, cavernous sinus invasion, compression of the optic chiasm, hypopituitarism, immunohistochemical (IHC) staining pattern of the adenoma, and insulin-like growth factor-1 (IGF-1) level, in acromegalic patients who had undergone
-
Analyzing structural differences between insulin receptor (IR) and IGF1R for designing small molecule allosteric inhibitors of IGF1R as novel anti-cancer agents. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-08-27 Nasima Bano,Md Mehedi Hossain,Aadil Qadir Bhat,Mir Owais Ayaz,Monika Kumari,Padmani Sandhu,Yusuf Akhter,Mohd Jamal Dar
IR and insulin-like growth factor-1 receptor (IGF-1R) share high degree of sequence and structural similarity that hinders the development of anticancer drugs targeting IGF1R, which is dysregulated in many cancers. Although IR and IGF1R mediate their activities through similar signalling pathways, yet they show different physiological effects. The exact molecular mechanism(s) how IR and IGF1R exert
-
Assessing insulin sensitivity and resistance in syndromes of severe short stature. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-07-28 Jaime Guevara-Aguirre,Enrique Teran,Daniela Lescano,Carolina Guevara,Alexandra Guevara,Jannette Saavedra,Patricio Procel,Clive Wasserfall,Antonio W D Gavilanes
Individuals affected with two genetic syndromes identified in Ecuador have severe short stature and diminished insulin secretion, along with essentially different GH counterregulatory effects on insulin action, which leads to the appearance of opposing metabolic phenotypes. In the case of Laron syndrome, subjects have enhanced insulin sensitivity and diminished incidence of type 2 diabetes mellitus
-
Role of growth hormone signaling pathways in the development of atherosclerosis. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-07-19 Mayumi Ishikawa,Junko Toyomura,Takashi Yagi,Koji Kuboki,Toshisuke Morita,Hitoshi Sugihara,Takahisa Hirose,Shiro Minami,Gen Yoshino
Objective The direct actions of growth hormone (GH) in the development of atherosclerosis are unclear. The goal of this study was to characterize GH-induced changes in expression of signaling pathway elements and other proteins that may be related to atherosclerosis. Methods Human umbilical vein endothelial cells (HUVEC) and THP-1, a human acute monocytic leukemia cell line, were stimulated by exposure
-
Adherence and long-term outcomes of therapy in paediatric patients in Greece using the easypod™ electromechanical device for growth hormone treatment: The phase IV multicentre easypod™ connect observational study (ECOS). Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-07-18 E Charmandari,E Vlachopapadopoulou,E M Kyritsi,D Sakellariou,E Koledova,K Nespithal,S Michalacos
Background The easypod™ injection device allows automatic recording and transmission of adherence data from patients receiving recombinant human growth hormone (rhGH [Saizen®]) to treat growth disorders. This analysis aimed to evaluate the adherence of Saizen® administered via easypod™ in a cohort of Greek patients from the easypod™ connect observational study (ECOS). Methods The phase IV, open-label
-
Crosstalk between the growth hormone/insulin-like growth factor-1 axis and the gut microbiome: A new frontier for microbial endocrinology. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-07-18 Elizabeth A Jensen,Jonathan A Young,Samuel C Mathes,Edward O List,Ronan K Carroll,Jaycie Kuhn,Maria Onusko,John J Kopchick,Erin R Murphy,Darlene E Berryman
Both the GH/IGF-1 axis and the gut microbiota independently play an important role in host growth, metabolism, and intestinal homeostasis. Inversely, abnormalities in GH action and microbial dysbiosis (or a lack of diversity) in the gut have been implicated in restricted growth, metabolic disorders (such as chronic undernutrition, anorexia nervosa, obesity, and diabetes), and intestinal dysfunction
-
Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-07-17 Ling Hou,Yan Liang,Wei Wu,Han-Hua Lin,Xiao-Ping Luo,Yan-Qin Ying
Purpose The present study aimed to compare the efficacy and safety of recombinant human growth hormone (rhGH) therapy between children with idiopathic short stature (ISS) and growth hormone deficiency (GHD). Methods A total of 150 pediatric patients with ISS and 153 pediatric patients with GHD who received rhGH treatment for more than one year from 2005 to 2016 were enrolled. Growth velocity (GV);
-
The significance of estrogen receptors in acromegaly: Are they useful as predictors of prognosis and therapy regimen? Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-07-17 Selma Ozturk,Hamiyet Donmez-Altuntas,Figen Ozturk,Ali Kurtsoy,Ferhat Gokay,Yasin Simsek,Fahri Bayram
Objective In this study, we considered to assess the presence of estrogen receptors (ER) and the expression of estrogen receptor genes (ESR) in the surgical tissue samples of acromegaly patients and the control group patients with nonfunctioning adenoma and their association with disease activity. We also aimed to determine the significance of ER positivity in acromegaly patients and to find out whether
-
Long-term endocrinological outcomes of gamma knife radiosurgery in acromegaly patients Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-07-15 Meliha Melin Uygur; Oğuzhan Deyneli; Dilek Gogas Yavuz
Gamma knife radiosurgery (GKS) is a treatment option for recurrent or persistent disease in patients with acromegaly. Objective We aimed to retrospectively evaluate acromegaly patients who had undergone GKS in terms of pituitary hormone status, efficacy of GKS, and prognostic factors. Method One-hundred and ten acromegaly patients who underwent GKS, and who were referred to our outpatient endocrinology
-
Growth hormone ameliorates high glucose-induced steatosis on in vitro cultured human HepG2 hepatocytes by inhibiting de novo lipogenesis via ChREBP and FAS suppression. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-07-15 Eréndira Villanueva-Ortega,Lucia A Méndez-García,Guadalupe N Garibay-Nieto,Estibalitz Laresgoiti-Servitje,Patricia Medina-Bravo,Alfonso Olivos-García,Martín H Muñoz-Ortega,Javier Ventura-Juárez,Galileo Escobedo
Objective: Growth hormone (GH) deficiency has been associated with increased steatosis but the molecular mechanism has not been fully elucidated. We investigated the effect of GH on lipid accumulation of HepG2 cells cultured on an in vitro steatosis model and examined the potential involvement of insulin-like growth factor 1 (IGF-1) as well as lipogenic and lipolytic molecules. Methods: Control and
-
Pregnancy-associated plasma proteins and Stanniocalcin-2 - Novel players controlling IGF-I physiology. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-07-04 Jan Frystyk,Enrique Teran,Mette Faurholdt Gude,Mette Bjerre,Rikke Hjortebjerg
IGF-I was originally discovered as a GH-dependent growth factor stimulating longitudinal growth. Currently, however, it has become evident that the biological activities of IGF-I extend well beyond those of a simple growth factor and impact such processes as insulin sensitivity, aging, cancer and cardiovascular disease. The vast majority of IGF-I is tightly bound to IGF-binding proteins (IGFBPs), which
-
Effect of amino acids on IGF1 gene expression in human myotubes and skeletal muscle. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-04-28 Egor M Lednev,Irina V Kravchenko,Vladimir A Furalyov,Evgeny A Lysenko,Iulia S Lemesheva,Alexandr A Grushin,Vadim E Dubrov,Olga L Vinogradova,Daniil V Popov
Objective Insulin-like growth factor I (IGF1) is an important regulator of collagen and extracellular matrix protein expression. We aimed to evaluate the effect of amino acids (AAs) on expression of IGF1 and IGF1-dependent genes in human myotubes and skeletal muscle and supposed that AAs administration increases IGF1 levels in blood and expression of IGF1 and IGF1-dependent genes in trained skeletal
-
The acromegaly registry of ten different centers in Turkey. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-04-27 Çağlar Keskin,Özgür Demir,Alper Çağrı Karcı,Dilek Berker,Zeynep Cantürk,Güzin Fidan Yaylali,Şenay Topsakal,Reyhan Ersoy,Fahri Bayram,Melek Eda Ertörer,Emre Bozkırlı,Filiz Haydardedeoğlu,Esra Nur Ademoğlu Dilekçi,Seyid Ahmet Ay,Güven Barış Cansu,Mustafa Şahin,Rıfat Emral,Demet Çorapçıoğlu
Objectives To describe biochemical and clinical features, and therapeutic outcomes of acromegaly patients in Turkey. Methods Retrospective multicenter epidemiological study of 547 patients followed in 10 centers of the Turkish Acromegaly registry. Results A total of 547 acromegaly patients (55% female) with a median age of 41 was included in this study. Majority of patients had a macroadenoma (78%)
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-04-15 Beate Klaus,Richard Sachse,Nicola Ammer,Nicky Kelepouris,Vlady Ostrow
Objective Macimorelin is an orally active ghrelin receptor agonist indicated for the diagnosis of adult growth hormone (GH) deficiency in the United States. This phase 1 study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of macimorelin (including a supratherapeutic dose to be used in a thorough QT trial) in healthy adults. Design Participants
-
Mechanisms of putative IGF-I receptor resistance in active acromegaly. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-04-06 Joseph A M J L Janssen
Acromegaly is a disease characterized by overproduction of growth hormone (GH). As a consequence of excessive GH secretion, circulating insulin-like growth factor-I (IGF-I) is elevated in active (untreated) acromegaly. IGF-I is often used as a marker of disease activity and growth hormone status in acromegaly. Although IGF-I can directly improve insulin sensitivity and glucose uptake in muscles, the
-
The effect of combined functional training on BDNF, IGF-1, and their association with health-related fitness in the multiple sclerosis women. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-04-02 Elnaz Abbaspoor,Mohammadreza Zolfaghari,Babak Ahmadi,Kazem Khodaei
Objective Exercise-induced changes in the neurotrophic factors and the physical function are essential for the rehabilitation of the multiple sclerosis (MS) persons. The aim of this study was investigating of effectiveness of the combined functional training (CFT) on brain-derived neurotrophic factor (BDNF), insulin-like growth factor-1 (IGF-1), and their association with health-related fitness in
-
A rationale for the treatment of short stature in children with the combination of recombinant human growth hormone (rhGH) and recombinant human insulin-like growth factor-I (rhIGF-I). Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-03-31 George M Bright,Juan Francisco Fierro-Renoy
Both rhGH and rhIGF-I are signaling molecules with the capacity to restore the rate of growth in certain subsets of slowly growing children. In some instances, heights attained at or near the time of cessation of linear growth are indistinguishable from the height distribution of the community as a whole or from the height distribution expected based on the heights of biological parents. The GH: IGF-I
-
Treatment of the adult growth hormone deficiency syndrome with growth hormone: What are the implications for other hormone replacement therapies for hypopituitarism? Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-03-23 Gustavo Fierro,Andrew R Hoffman
When initiating growth hormone replacement therapy, it is important to consider a patient's other pituitary hormone replacement medications, as adjustments are often necessary. Growth hormone therapy can increase the metabolism of hydrocortisone or endogenous cortisol, unmasking borderline ACTH deficiency and leading to the development of adrenal insufficiency and adrenal crisis. In addition, growth
-
Potential applications for rhIGF-I: Bone disease and IGFI. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-03-23 Marisol Bahamonde,Madhusmita Misra
Growth hormone (GH) and insulin like growth factor-I (IGFI) are key bone trophic hormones, whose rising levels during puberty are critical for pubertal bone accrual. Conditions of GH deficiency and genetic resistance impact cortical and trabecular bone deleteriously with reduced estimates of bone strength. In humans, conditions of undernutrition (as in anorexia nervosa (AN), or subsequent to chronic
-
Growth hormone receptor deficiency in humans associates to obesity, increased body fat percentage, a healthy brain and a coordinated insulin sensitivity Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-02-19 Jaime Guevara-Aguirre, Enrique Teran, Daniela Lescano, Alexandra Guevara, Carolina Guevara, Valter Longo, Antonio W.D. Gavilanes
Background We have shown that subjects with Laron syndrome (LS) due to growth hormone receptor deficiency (GHRD) and their relatives have comparable brain structure and function; moreover, the brain of individuals affected with GHRD appears like those of younger people. While the functionally absent growth hormone receptor and the diminished concentrations of the insulin-like growth factor-I have been
-
Nicotine inhibits expression of Prrx1 in pituitary stem/progenitor cells through epigenetic regulation, leading to a delayed supply of growth-hormone-producing cells Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-02-19 Ayaka Hibara, Takahiro Yamaguchi, Miki Kojima, Yoshiaki Yamano, Masashi Higuchi
Objective Nicotine, a toxic component of smoking, adversely affects animal growth and reproduction by decreasing secretion of anterior pituitary hormones. However, it has not been clarified whether nicotine inhibits the supply of endocrine cells in the pituitary gland. The present study investigated short- and long-term effects of persistent nicotine exposure on the pituitary glands of young animals
-
The IGF system and longitudinal growth in preterm infants in relation to gestational age, birth weight and gender. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-02-19 Ann Hellström,Jon Sigurdsson,Chatarina Löfqvist,Gunnel Hellgren,Anna Kistner
Objective Growth factors in the blood of very preterm infants may reflect growth and contribute to the understanding of early development. We investigated postnatal levels of insulin-like growth factors (IGFs) in infants born very preterm and related them to early growth development. Design Blood samples were analyzed weekly for IGF-I, IGF-II, IGF binding protein (BP)-1, IGFBP-3, and acid-label subunit
-
Changes in plasma amino acids metabolites, caused by long-term IGF-I deficiency, are reversed by IGF-I treatment - A pilot study. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-02-11 Chen Barazani,Haim Werner,Zvi Laron
Laron Syndrome (LS), (OMIM# 262500), a rare recessively inherited disease caused by deletions or mutations of the GH receptor, gene characterized by dwarfism with low or undetectable serum IGF-I in the presence of high serum GH. In addition to dwarfism, the IGF-I deficiency leads to metabolic abnormalities including aberrations in protein biosynthesis and homeostasis. The only available treatment for
-
-
The clinician's role in promoting resiliency for individuals and families with growth anomalies. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-01-28 Howard D Silverman,Michelle Grunauer
Some recent clinic and population-based studies suggest that severe short stature is not associated with significant behavioral and psychological problems, however collectively studies on this topic are variable and frequently contradictory. In light of these contradictory sources, it is important to recognize that there may be some children for whom growth failure is disabling. Many of such children
-
Effects of a home-based exercise program on the insulin-like growth factor axis in patients operated for colorectal cancer in Sweden: Results from the randomised controlled trial PHYSSURG-C. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-01-28 Aron Onerup,Sven-Egron Thörn,Eva Angenete,David Bock,Elin Grybäck Gillheimer,Eva Haglind,Hanna Nilsson
Objectives We report results from a subgroup within the ongoing PHYSSURG-C trial with the aim to examine effects of exercise on IGF-1 and IGFBP-3 in patients undergoing colorectal cancer surgery. Design Randomised controlled trial. Setting A Swedish university hospital. Participants Between 2015 and 2016, 217 patients were enrolled (I = 106, C = 111), with 122 patients that had given blood samples
-
Development of a novel assay for IGFBP-2 complexed with IGF-I and-II in human serum. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-01-21 Jonas Agerholm,Rikke Hjortebjerg,Ulrick Espelund,Torben Riis Rasmussen,Birgitte Folkersen,Mette Bjerre,Jan Frystyk
Background Insulin-like growth factor binding-protein 2 (IGFBP-2) was originally identified as an IGF-carrier, governing IGF half-life, tissue accessibility and biological effects. Later, IGFBP-2 was discovered to possess IGF-independent effects. IGFBP-2 circulates in several forms, as free protein, complexed with IGF-I or IGF-II, or as IGFBP-2 fragments. The various IGFBP-2 forms are all included
-
The combined frequencies of the IL-6 G-174C and IGFBP3 A-202C polymorphisms among swimmers and runners. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-01-14 Sigal Ben-Zaken,Yoav Meckel,Dan Nemet,Eias Kassem,Alon Eliakim
Previous studies have demonstrated that compared to runners, swimmers carry a higher prevalence of the IL-6 -174C polymorphism and lower single nucleotide polymorphism frequencies of the IGF system. Purpose The aim of the present study was to assess the combined frequency of the IL-6 -174G/C and IGFBP3 -202A/C polymorphisms among track and field athletes and swimmers. Methods Track and field athletes
-
Therapy with recombinant human IGF-1 for children with primary insulin-like growth factor-I deficiency. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2020-01-13 Philippe Backeljauw
The efficacy and safety of IGF-1 therapy in patients with severe primary IGF-I deficiency has been evaluated for more than two decades. Most of the therapeutic experience comes from treating the more severe IGF-I deficient patients, who usually present with a phenotype characteristic of growth hormone receptor deficiency or Laron syndrome. Although most of these patients do not experience enough catchup
-
Linkage between growth retardation and pituitary cell morphology in a dystrophin-deficient pig model of Duchenne muscular dystrophy. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-12-31 I Hofmann,E Kemter,N Theobalt,S Fiedler,M Bidlingmaier,A Hinrichs,M Aichler,K Burkhardt,N Klymiuk,E Wolf,R Wanke,A Blutke
Objective Human patients with Duchenne muscular dystrophy (DMD) commonly exhibit a short stature, but the pathogenesis of this growth retardation is not completely understood. Due to the suspected involvement of the growth hormone/insulin-like growth factor 1 (GH/IGF1) system, controversial therapeutic approaches have been developed, including both GH- administration, as well as GH-inhibition. In the
-
A novel heterozygous STAT5B variant in a patient with short stature and partial growth hormone insensitivity (GHI) Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-12-27 Laura Ramírez, Nora Sanguineti, Paula Scaglia, Ana Keselman, María Gabriela Ballerini, Liliana Karabatas, Estefanía Landi, Julia Castro, Sabina Domené, Patricia Pennisi, Héctor Jasper, Rodolfo A. Rey, Martín Vázquez, Horacio Domené, Ignacio Bergadá, Mariana Gutiérrez
Background The most frequent monogenic causes of growth hormone insensitivity (GHI) include defects in genes encoding the GH receptor itself (GHR), the signal transducer and activator of transcription (STAT5B), the insulin like-growth factor type I (IGF1) and the acid-labile subunit (IGFALS). GHI is characterized by a continuum of mild to severe post-natal growth failure. Objective To characterize
-
Tissue-specific disruption of the growth hormone receptor (GHR) in mice: An update. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-12-24 Silvana Duran-Ortiz,Vanessa Noboa,John J Kopchick
The Growth hormone receptor (GHR) is expressed in many cells/tissues in the body. To investigate the specific metabolic effects of GH action in distinct tissues, several tissue-specific GHR gene disrupted or knockout (KO) mouse lines have been generated. Previously, we have described the effects of GHRKO in several known insulin sensitive tissues, namely liver, muscle and adipose tissue. In this review
-
Growth hormone increases dendritic spine density in primary hippocampal cell cultures Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-12-11 Erik Nylander, Sofia Zelleroth, Frida Stam, Fred Nyberg, Alfhild Grönbladh, Mathias Hallberg
Objective Growth hormone (GH) is widely known for its peripheral effects during growth and development. However, numerous reports also suggest that GH exert pro-cognitive, restorative, and protective properties in the brain. In in vitro studies, the detection of dendritic spines, small protrusions extending from axons, can act as a marker for cognition-related function as spine formation is considered
-
Volumetric Absorptive Microsampling (VAMS) technology for IGF-1 quantification by automated chemiluminescent immunoassay in dried blood Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-12-09 A. Marchand, I. Roulland, F. Semence, M. Audran
For medical diagnostics and anti-doping analyses, insulin-like growth factor 1 (IGF-1) can be measured in serum using automated chemiluminescent immunoassays. The aim of this study was to assess the feasibility of using dried blood instead of serum to measure IGF-1 concentrations with an automated IGF-1 immunoassay and to evaluate if IGF-1 concentrations from dried capillary blood and serum were comparable
-
p.R209H GH1 variant challenges short stature assessment Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-12-03 Nora Sanguineti, Debora Braslavsky, Paula A. Scaglia, Ana Keselman, Maria G. Ballerini, Maria G. Ropelato, Sofia Suco, Sebastian Vishnopolska, Ariel J. Berenstein, Héctor Jasper, Horacio M. Domené, Rodolfo A. Rey, Maria I. Pérez Millán, Sally A. Camper, Ignacio Bergadá
Objective: to describe the marked variability in clinical and biochemical patterns that are associated with a p.R209H GH1 missense variant in a large Argentinean pedigree, which makes the diagnosis of GHD elusive. Design: We describe a non-consanguineous pedigree composed by several individuals with short stature, including 2 pediatric patients with typical diagnosis of isolated growth hormone deficiency
-
From dwarves to giants: South American's contribution to the history of growth hormone and related disorders Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-12-02 Cesar Luiz Boguszewski, Margaret Cristina da Silva Boguszewski, Wouter W. de Herder
The aim of this article is to present a historical review on giants and dwarves living in South America and the contribution of South America's researchers to scientific advances on growth hormone (GH) and human disorders related to GH excess and GH deficiency (GHD). We went back in time to investigate facts and myths stemming from countless reports of giants who lived in the Patagonia region, focusing
-
Bioactive growth hormone in humans: Controversies, complexities and concepts Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-11-27 Wesley C. Hymer, Mary J. Kennett, Samir K. Maji, Kristin L. Gosselink, Gary E. McCall, Richard E. Grindeland, Emily M. Post, William J. Kraemer
Objective To revisit a finding, first described in 1978, which documented existence of a pituitary growth factor that escaped detection by immunoassay, but which was active in the established rat tibia GH bioassay. Methods We present a narrative review of the evolution of growth hormone complexity, and its bio-detectability, from a historical perspective. Results In humans under the age of 60, physical
-
Elevated levels of IL-6 and IGFBP-1 predict low serum IGF-1 levels during continuous infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-11-09 Susanna Klevebro,Gunnel Hellgren,Ingrid Hansen-Pupp,Dirk Wackernagel,Boubou Hallberg,Jan Borg,Aldina Pivodic,Lois Smith,David Ley,Ann Hellström
Objective Steady state insulin-like growth factor-1 (IGF-1) levels vary significantly during continuous intravenous infusion of recombinant human insulin-like growth factor-1/recombinant human insulin-like growth factor binding protein-3 (rhIGF-1/rhIGFBP-3) in the first weeks of life in extremely preterm infants. We evaluated interleukin-6 (IL-6) and insulin-like growth factor binding protein-1 (IGFBP-1)
-
IGF research 2016-2018. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2019-11-06 Shin-Ichiro Takahashi
This article is based on my presentation at the 9th International Congress of the Growth Hormone Research and Insulin-like Growth Factor (IGF) Societies at Seattle, USA on 17th, September 2018. In the article, after a general introduction to IGF research, I briefly review the IGF research being published from 2016 to 2018, focusing on what I believe represent the most interesting areas of progress
-
Corrigendum to "Assessment of quality of life on 4-year growth hormone therapy in Japanese patients with adult growth hormone deficiency: A post-marketing, multicenter, observational study" [Growth Hormon. IGF Res. 36 (2017) 36-43]. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2018-02-21 Hitoshi Ishii,Akira Shimatsu,Hiromi Nishinaga,Osamu Murai,Kazuo Chihara
-
Preface. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2018-01-10 Carlos Montúfar,Ximena Córdova,Santiago Gangotena,Diego Quiroga,Michelle Grunauer
-
Foreword from the guest editors. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2018-01-04 Jaime Guevara-Aguirre,Enrique Teran,Ron Rosenfeld
-
Corrigendum to "Professor Kerstin Hall (1929-2017): Pioneer in the field of Growth Hormone and IGF Research" [Growth Horm. IGF Res. 34 (2017) 28-30. doi: 10.1016/j.ghir.2017.05.001. Epub 2017 May 3]. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2017-07-08 M S Lewitt,A L Hulting
-
Professor Kerstin Hall (1929-1917): Pioneer in the field of growth hormone and IGF research. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2017-05-14 Moira S Lewitt,Anna-Lena Hulting
-
-
Preface. Growth Horm. IGF Res. (IF 1.618) Pub Date : 2016-04-27